Metalloproteinases and Recurrent Corneal Erosion Syndrome
- Conditions
- Recurrent Corneal Erosion Syndrome
- Interventions
- Other: in vitro immuno-histo-chemical analysis of corneal epithelium
- Registration Number
- NCT02891694
- Lead Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Brief Summary
Recurrent corneal erosion (RCE) syndrome can be observed either in the context of a dystrophy of the basement membrane or following corneal trauma. This syndrome is characterized by recurrent episodes of ocular pain more or less associated with localized separations between the outer epithelium and the epithelial basal lamina (basement membrane) because of anchorage abnormalities between these two corneal layers. This could be the result of an increased expression of metalloproteinases cleaving the hemidesmosomes which anchor epithelium to the basement membrane.
The investigators hypothesis is that episodes of RCEs are favored by a hyper- expression of matricial metalloprotease 9 (MMP-9) induced by EMMPRIN and Galectin-3. The identification of such induction could lead to development of therapeutics inhibiting EMMPRIN and Galectin- 3 in the RCE syndrome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 19
- Age > 18 years old
- Recurrent Corneal Erosion Syndrome, with - failure of medical treatment and therapeutic photokeratectomy scheduled
- Photorefractive surgical keratectomy (control patients)
- Opposition to participation in the study
- Known pregnancy or breast-feeding patient
- No medical insurance coverage
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description control patients (refractive surgery) in vitro immuno-histo-chemical analysis of corneal epithelium - recurrent corneal erosion in vitro immuno-histo-chemical analysis of corneal epithelium -
- Primary Outcome Measures
Name Time Method expression of the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) in epithelial cells baseline
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Fondation Opthalmologique A de Rothschild
🇫🇷Paris, France